+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) - Market Insights and Market Forecast - 2030

  • ID: 5010964
  • Report
  • April 2020
  • Region: Global
  • 200 pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

  • Gilead Sciencesc
  • Novartis
  • MORE
‘CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) - Market Insights and Market Forecast-2030' report delivers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) and market trends in the 6MM, i.e., United States and EU5 (Germany, Spain, Italy, France and United Kingdom).

The CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) market report provides current treatment practices, emerging therapies, CAR T-Cell Therapy for Non-Hodgkin's lymphoma market share of the individual therapies, current and forecasted CAR T-Cell Therapy for Non-Hodgkin's lymphoma market size from 2017 to 2030 segmented by US and EU markets. The Report also covers current CAR T-Cell Therapy for Non-Hodgkin's lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2017-2030

CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Disease Understanding and Treatment Algorithm

CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Overview

Chimeric antigen receptor (CAR) T-cell therapy involves genetic modification of patient's autologous T-cells to express a CAR, specific for a tumor antigen, followed by ex vivo cell expansion and re-infusion back to the patient. CAR T-cells are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains.

NHL is another type of blood cancer affecting the lymphocytes that witness high number of relapse cases. Diffuse large B-cell lymphoma (DLBCL) is the most common type of NHL, accounting for about 22% of newly diagnosed cases of B-cell NHL in the United States.

CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Treatment

It covers the details of conventional and current medical therapies available as the CAR T-Cell Therapy in Non-Hodgkin's lymphoma market for the treatment of this condition. It also provides the country-wise treatment guidelines and algorithm across the United States and Europe.

The CAR T-Cell Therapy for Non-Hodgkin's lymphoma market report gives a thorough understanding of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Non-Hodgkin's lymphoma (NHL) in the US and Europe.

CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Drug Chapters

Drug chapter segment of the CAR T-Cell Therapy for Non-Hodgkin's lymphoma report encloses the detailed analysis of Non-Hodgkin's lymphoma marketed CAR T-Cell Therapies and late stage (Phase-III and Phase-II) pipeline therapies. It also helps to understand the CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included therapy and the latest news and press releases.

CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Marketed Therapies

Kymriah (tisagenlecleucel): Novartis

Kymriah (tisagenlecleucel), formerly known as CTL019, is a prescription cancer treatment approved for the use in patients up to 25 years old who have r/r ALL that and adult patients with r/r large B-cell lymphoma after two or more lines of systemic therapy including DLBCL not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Product details in the report.
CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Emerging Therapies
KTE-X19: Gilead Sciences
KTE-X19 is an investigational CD19 CAR T-cell therapy. KTE-X19 has the same construct as axicabtagene ciloleucel; however, the manufacturing process for KTE-X19 differs from that of axicabtagene ciloleucel and includes the enrichment of lymphocytes. Lymphocyte enrichment is necessary in certain B-cell malignancies for which KTE-X19 in under investigation. KTE-X19 is currently in Phase I/II trials in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). And phase II in Relapsed/Refractory Mantle Cell Lymphoma.

Product details in the report.

CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Market Outlook

The CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Non-Hodgkin's lymphoma market trends by analyzing the impact of current CAR T-Cell Therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Non-Hodgkin's lymphoma market trend of each marketed CAR T-Cell Therapy and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, CAR T-Cell Therapy for Non-Hodgkin's lymphoma market in 6MM is expected to change in the study period 2017-2030.

CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Therapies Uptake

This section focusses on the rate of uptake of the potential CAR T-Cell Therapies recently launched in the Non-Hodgkin's lymphoma market or expected to get launched in the market during the study period 2017-2030. The analysis covers Non-Hodgkin's lymphoma market uptake by CAR T-Cell Therapies; patient uptake by therapies; and sales of each therapy.

This helps in understanding the CAR T-Cell Therapies with the most rapid uptake, reasons behind the maximal use of new therapies and allows the comparison of the therapies on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses key players for CAR T-Cell Therapy for the treatment of Non-Hodgkin's lymphoma involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Non-Hodgkin's lymphoma (NHL) emerging CAR T-Cell Therapies.

Reimbursement Scenario in CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In report we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.

KOL - Views

To keep up with current market trends, we take KOLs and SME's opinion working in CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or CAR T-Cell Therapy for Non-Hodgkin's lymphoma market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive & Market Intelligence analysis of the CAR T-Cell Therapy for Non-Hodgkin's lymphoma Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
  • The report covers the descriptive overview of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL), explaining causes, signs and symptoms, pathophysiology and currently available therapies for NHL and
  • Comprehensive insight has been provided into the CAR T-Cell Therapy for Non-Hodgkin's lymphoma treatment in the US and EU5
  • Additionally, an all-inclusive account of both the current and emerging CAR T-Cell Therapies for Non-Hodgkin's lymphoma (NHL) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of CAR T-Cell Therapy for Non-Hodgkin's lymphoma market; historical and forecasted is included in the report, covering drug outreach in the US and EU5
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global CAR T-Cell Therapy for Non-Hodgkin's lymphoma market
Report Highlights
  • In the coming years, CAR T-Cell Therapy for Non-Hodgkin's lymphoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the therapy manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing CAR T-Cell Therapies for Non-Hodgkin's lymphoma (NHL). Launch of emerging therapies, will significantly impact the Non-Hodgkin's lymphoma market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL)
  • The in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Report Insights
  • Therapeutic Approaches
  • CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Pipeline Analysis
  • CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Report Key Strengths
  • US and EU5 (France, Germany, Italy, Spain and United Kingdom) Coverage
  • Key Cross Competition
  • Highly Analyzed Market
  • CAR T-cell Therapy Uptake
CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Questions

Market Insights:
  • What was the CAR T-Cell Therapy for Non-Hodgkin's lymphoma Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the CAR T-Cell Therapy for Non-Hodgkin's lymphoma total market size as well as market size by therapies across the US and EU5 during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across the US and EU5 and which country will have the largest CAR T-Cell Therapy for Non-Hodgkin's lymphoma market size during the forecast period (2017-2030)?
  • At what CAGR, the CAR T-Cell Therapy for Non-Hodgkin's lymphoma market is expected to grow in the US and EU5 during the forecast period (2017-2030)?
  • What would be the CAR T-Cell Therapy for Non-Hodgkin's lymphoma market outlook across the US and EU5 during the forecast period (2017-2030)?
  • What would be the CAR T-Cell Therapy for Non-Hodgkin's lymphoma market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
Current Treatment Scenario, Marketed and Emerging CAR T-cell Therapies:
  • What are the current options of CAR T-Cell Therapy for the treatment of Non-Hodgkin's lymphoma along with the approved therapy?
  • What are the current treatment guidelines for Non-Hodgkin's lymphoma in USA and Europe?
  • What are the Non-Hodgkin's lymphoma marketed CAR T-Cell Therapies available and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy etc.?
  • How many companies are developing CAR T-Cell Therapies for the treatment of Non-Hodgkin's lymphoma (NHL)?
  • How many CAR T-Cell Therapies are developed by each company for the treatment of Non-Hodgkin's lymphoma (NHL)?
  • How many emerging CAR T-Cell Therapies are in mid stage, and late stage of development for the treatment of Non-Hodgkin's lymphoma (NHL)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL)?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) and their status?
  • What are the key designations that have been granted for the emerging CAR T-Cell Therapies for Non-the treatment of Hodgkin's lymphoma (NHL)?
  • What are the global historical and forecasted market of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL)?
Reasons to Buy
  • The report will help in developing business strategies by understanding trends shaping and driving the CAR T-Cell Therapy for Non-Hodgkin's lymphoma market
  • To understand the future market competition in the CAR T-Cell Therapy for Non-Hodgkin's lymphoma market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for CAR T-Cell Therapy for Non-Hodgkin's lymphoma in US and Europe (Germany, Spain, Italy, France and United Kingdom)
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for CAR T-Cell Therapy for Non-Hodgkin's lymphoma market
  • To understand the future market competition in the CAR T-Cell Therapy for Non-Hodgkin's lymphoma market
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Gilead Sciencesc
  • Novartis
  • MORE
1 Key Insights

2 Executive Summary

3 CAR T-Cell Therapy for NHL Market Overview at a Glance
3.1 CAR T-Cell Therapy for NHL Total Market Share (%) Distribution in 2017
3.2 CAR T-Cell Therapy for NHL Total Market Share (%) Distribution in 2030

4 CAR T-Cell Therapy: Background and Overview
4.1 Introduction
4.1.1 CARs Generations
4.1.2 Genetic Engineering of T-Cells
4.1.3 How CAR T-Cell Therapy Works
4.2 Current challenges in CAR T
4.2.1 Therapeutic side effects
4.2.2 CAR T-cells ─ lack of success
4.3 CAR T-cell therapy: Route to reimbursement

5 Treatment Algorithm, Current Treatment, and Medical Practices
5.1 CAR T-Cell Therapy for NHL Treatment and Management
5.2 CAR T-Cell Therapy for NHL Treatment Algorithm

6 Unmet Needs

7 Key Endpoints of NHL Treatment

8 Marketed CAR T-Cell Therapies for NHL
8.1 List of Marketed Products in the 6MM
8.2 KYMRIAH: NOVARTIS
8.2.1 Product Description
8.2.2 Regulatory Milestones
8.2.3 Other Developmental Activities
8.2.4 Pivotal Clinical Trials
8.2.5 Summary of Pivotal Clinical Trial
8.3 YESCARTA: Kite Pharma (Gilead Sciences)
8.3.1 Product Description
8.3.2 Regulatory Milestones
8.3.3 Other Developmental Activities
8.3.4 Pivotal Clinical Trials
8.3.5 Summary of Pivotal Clinical Trial

9 Emerging CAR T-Cell Therapies for NHL
9.1 Key Cross
9.1.1 KTE-X19 : Gilead Sciences
9.1.1.1 Product Description
9.1.1.2 Other Developmental Activities
9.1.1.3 Clinical Development
9.1.1.5 Safety and Efficacy
9.1.1.6 Product Profile
9.1.2 JCAR017: Celgene Corporation (a BMS company)
9.1.2.1 Product Description
9.1.2.2 Other Developmental Activities
9.1.2.3 Clinical Development
9.1.2.4 Safety and Efficacy
9.1.2.5 Product Profile

10 CAR T-Cell Therapy for NHL: Six Major Market Analysis
10.1 Key Findings
10.2 CAR T-Cell Therapy for NHL Market Size in 6MM
10.3 CAR T-Cell Therapy for NHL Market Size by Therapies in the 6MM

11 Attribute analysis

12 6MM: Market Outlook
12.1 United States
12.1.1 Total Market Size of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in the United States
12.1.2 Market Size of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in the United States
12.2 EU-5 Market Size
12.2.1 Germany
12.2.1.1 Total Market size of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in Germany
12.2.1.2 Market Size of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in Germany
12.2.2 France
12.2.2.1 Total Market Size of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in France
12.2.2.2 Market Size of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in France
12.2.3 Italy
12.2.3.1 Total Market Size of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in Italy
12.2.3.2 Market Size of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in Italy
12.2.4 Spain
12.2.4.1 Total Market Size of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in Spain
12.2.4.2 Market Size of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in Spain
12.2.5 United Kingdom
12.2.5.1 Total Market Size of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in the United Kingdom
12.2.5.2 Market Size of CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) in the United Kingdom

13 CAR T-Cell Therapy for NHL Clinical Trials in 6MM

14 KOL Views - CAR T-Cell Therapy for NHL

15 Market Drivers

16 Market Barriers

17 Appendix
17.1 Bibliography
17.2 Report Methodology

18 Capabilities

19 Disclaimer

20 About the Publisher
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Novartis
  • Gilead Sciencesc
Note: Product cover images may vary from those shown
Adroll
adroll